Resistance to bevacizumab occurs through a spatiotemporal adaptation process where tumours bypass VEGF‐A blockade by activating redundant signalling pathways such as fibroblast growth factor (FGF), platelet‐derived growth factor (PDGF) and angiopoietins. The gene discussed is VEGFA; the disease is neoplasm.